Down Syndrome

Down syndrome is the most prevalent genetic disorder, occurring in one of every 700 live births. Until recently a therapeutic for individuals with Down syndrome seemed improbable, due to the large number of genes (extra chromosome 21) that could be responsible for the developmental disorder. Studies suggest that a 33-gene region of the chromosome appears critical for the cognitive deficit and that potentially one gene, Dyrk1a, may play a partial in the developmental cognitive impairment.

Our neurogenic therapeutic candidate for depression and post-traumatic stress disorder, NNI-351, also inhibits a protein, Dyrk1a protein, that is overproduced in Down syndrome individuals. The inhibition of the protein appears to play some role in how NNI-351 increases the production of new neurons in the hippocampus (area of attention, learning and memory), thus reducing the overall hyperactivity and increasing the learning and memory ability in Down syndrome transgenic mice. Of great importance, is that these beneficial effects of NNI-351 are disease-modifying and do not just mask the symptoms in this well established mouse model of Down syndrome. As stated elsewhere, a patent for NNI-351 has now been issued to Neuronascent by the United States patent office.

For more information on Down syndrome, please visit the NICHD website at

Increase in Neurons in Mice from NNI-351

  » Home
» News & Events
» Contact Us
Management Team
Directors & Advisors
Neurogenesis & Neuron Regeneration
Drug Discovery
Intellectual Property
Alzheimer's Disease
Parkinson's Disease
Down Syndrome
Hibernation and Ischemia
  © 2016 NeuroNascent, Inc. - All Rights Reserved
This website contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “will,” “expects,” and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this site and involve risks and uncertainties that could cause actual results to differ materially from current expectations.